US EditionPublished • loading... • Updated
Maze Therapeutics, Inc. (MAZE) Stock Analysis: Biotech Trailblazer With A 26.53% Upside Potential
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Maze Therapeutics, Inc. (MAZE) Stock Analysis: Biotech Trailblazer With A 26.53% Upside Potential
Maze Therapeutics, Inc. (NASDAQ: MAZE) emerges as a compelling player in the biotechnology sector, boasting a market capitalization of $1.44 billion. Operating out of South San Francisco, California, Maze is a clinical-stage biopharmaceutical firm focused on developing small molecule precision medicines targeting renal, cardiovascular, metabolic diseases, and obesity. With a current stock price of $29.90, Maze offers investors a potential upside…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
